Richardson A P, Mountford P J, Heyderman E, Coakley A J
Department of Nuclear Medicine, Kent and Canterbury Hospital, UK.
Nucl Med Commun. 1987 May;8(5):347-56. doi: 10.1097/00006231-198705000-00005.
A procedure for conjugating antibodies in batches with DTPA is described which yields pharmaceutical grade preparations that can be kept in frozen storage until required. Routine radiolabelling is then simply performed by adding 111In chloride to the sterile 'kit' vial. After 1h, a DTPA solution is added to make the preparation ready for use in patients. The effects of pH, DTPA to antibody ratio, and time of reaction were investigated to optimize the preparation. By this method the antibody-DTPA conjugates may be prepared and the quality control performed at regional nuclear medicine centres where facilities and expertise already exist. These 'kits' can then be distributed to other departments where the 111In is added as and when required in a similar way to the preparation of other radiopharmaceuticals.
本文描述了一种将抗体与二乙三胺五乙酸(DTPA)批量偶联的方法,该方法可制备出药物级制剂,这些制剂可冷冻保存直至需要使用。然后,只需向无菌“试剂盒”小瓶中加入氯化铟(111In)即可进行常规放射性标记。1小时后,加入DTPA溶液,使制剂可供患者使用。研究了pH值、DTPA与抗体的比例以及反应时间对制剂优化的影响。通过这种方法,可以制备抗体-DTPA偶联物,并在已经具备设施和专业知识的区域核医学中心进行质量控制。然后,这些“试剂盒”可以分发给其他部门,在这些部门,根据需要以与制备其他放射性药物类似的方式加入111In。